Fundraising Fox
Kivu Bioscience
26 employees on LinkedIn · 7 known investors
Find your way into Kivu Bioscience
Each arrow is one introduction. Sign up to fill in the first one.
Ask Edward van Wezel to introduce you to Sophia Randolph
You →Edward · together at Kivu Bioscience →Sophia
Sign up to find every way you can get introduced to Kivu Bioscience
- Your email: who you already know at Kivu Bioscience, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Kivu Bioscience team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
Founders & leadership
Investors · 7
How we know: BioGeneration Ventures's portfolio page · funding news · biogenerationventures.com · Not right? Tell us
How we know: the VCSheet dataset · Not right? Tell us
How we know: funding news · marketscreener.com · Not right? Tell us
Funding
SEC filings, press & company announcements$92M disclosed across 1 round · 2024
- $92MSeries AOct 2024 · 3 sources
Novo Holdings (lead), BioGeneration Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Kivu Bioscience do?
- Kivu Bioscience develops antibody-drug conjugate (ADC) therapeutics in clinical development, advancing a pipeline of cancer treatments through strategic partnerships and collaborations.
- Who are Kivu Bioscience's investors?
- Kivu Bioscience's investors include BioGeneration Ventures, BOM, Gimv, HealthCap, M Ventures, Red Tree Venture, Novo Holdings.
- How much funding has Kivu Bioscience raised?
- Kivu Bioscience has disclosed $92M raised across 1 round.